Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Polymorphic drug metabolism.

M V Relling1

  • 1Pharmacokinetics/Pharmacodynamics Laboratory, St. Jude Children's Research Hospital, Memphis, TN 38101.

Clinical Pharmacy
|December 1, 1989
PubMed
Summary
This summary is machine-generated.

Genetic variations in drug metabolism, including debrisoquin, N-acetylation, and mephenytoin polymorphisms, affect how individuals respond to medications. Understanding these genetic differences is key to personalized medicine and predicting drug efficacy and adverse effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group.

Clinical pharmacology and therapeutics·2017
Same author

New Pharmacogenomics Research Network: An Open Community Catalyzing Research and Translation in Precision Medicine.

Clinical pharmacology and therapeutics·2017
Same author

Response to "PNPLA3 rs738409 and Hepatotoxicity in Children With B-cell Acute Lymphoblastic Leukemia: A Validation Study in a Spanish Cohort".

Clinical pharmacology and therapeutics·2017
Same author

Infection-related complications during treatment for childhood acute lymphoblastic leukemia.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

The effect of body mass index at diagnosis on clinical outcome in children with newly diagnosed acute lymphoblastic leukemia.

Blood cancer journal·2017
Same author

Genetics of ancestry-specific risk for relapse in acute lymphoblastic leukemia.

Leukemia·2017
Same journal

Criteria for use of epoetin alfa in adult cancer and orthopedic-surgery patients.

Clinical pharmacy·1993
Same journal

Accuracy of unbound-quinidine concentration determination after ultrafiltration.

Clinical pharmacy·1993
Same journal

Modified Michaelis-Menten equation for estimating unbound-phenytoin concentrations.

Clinical pharmacy·1993
Same journal

Predicting vancomycin pharmacokinetics by using aminoglycoside pharmacokinetics.

Clinical pharmacy·1993
Same journal

Efficacy of nutritional supplements used by athletes.

Clinical pharmacy·1993
Same journal

Low-molecular-weight heparins for the treatment of deep-vein thrombosis.

Clinical pharmacy·1993
See all related articles

Area of Science:

  • Pharmacogenomics
  • Drug Metabolism
  • Genetic Polymorphisms

Background:

  • Three major drug metabolism genetic polymorphisms are well-characterized: debrisoquin (CYP2D6), N-acetylation (NAT2), and mephenytoin (CYP2C19).
  • These polymorphisms, leading to poor metabolizer phenotypes, are inherited as autosomal recessive traits.
  • Defects in specific cytochrome P450 enzymes underlie the debrisoquin and mephenytoin oxidative polymorphisms.

Purpose of the Study:

  • To review the key genetic polymorphisms in drug metabolism.
  • To discuss the prevalence and clinical significance of these polymorphisms.
  • To highlight the impact of genetic variations on interindividual drug response.

Main Methods:

  • Review of existing literature on debrisoquin, N-acetylation, and mephenytoin polymorphisms.

Related Experiment Videos

  • Analysis of prevalence data across different ethnic groups.
  • Summary of clinical consequences associated with poor metabolizer phenotypes.

    • Main Results:

    • Prevalence of poor metabolizers varies: debrisoquin (2-10%), mephenytoin (5% Caucasian, 20% Japanese), and slow acetylators (50% Caucasian/Black, 10% Japanese).
    • Numerous drugs are substrates for these metabolic pathways, with varying numbers for each polymorphism.
    • Poor metabolizers exhibit distinct adverse drug reactions, including hypotension (debrisoquin), neurological effects (sparteine, mephenytoin), and increased susceptibility to autoimmune diseases and toxicities (slow acetylators).

    Conclusions:

    • Genetic polymorphisms in drug metabolism significantly contribute to interindividual variability in drug disposition and response.
    • Awareness of these genetic variations is crucial for optimizing drug therapy and minimizing adverse events.
    • Further understanding of pharmacogenomics can lead to more precise and effective personalized medicine approaches.